NCT06658054View on ClinicalTrials.gov

Erector Spinae Plan Block (ESPB) with Dexmedetomidine and Dexamethasone in Lumbar Spine Fusion

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Lumbar Degenerative Disease
Interventions
DRUG

Adjuvant analgesia

Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.

DRUG

Control (Standard treatment)

Patient will receive standard ESPB with bupivacaine and normal saline

All Listed Sponsors
lead

University of Southern California

OTHER

NCT06658054 - Erector Spinae Plan Block (ESPB) with Dexmedetomidine and Dexamethasone in Lumbar Spine Fusion | Biotech Hunter | Biotech Hunter